Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Setmelanotide in Renal Impairment
NCT04348175Phase 1Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Apr 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of setmelanotide in Genetic obesity, Bardet–Biedl syndrome (BBS), pro-opiomelanocortin deficiency and 2 more (4 arms), sponsored by Rhythm Pharmaceuticals. Primary endpoints: Peak Plasma Concentration at 5 days and Area under the plasma concentration versus time curve at 5 days. Started Jul 2020; status: completed.
02
Drugs
setmelanotide
03
Conditions
Genetic obesityBardet–Biedl syndrome (BBS)pro-opiomelanocortin deficiencyleptin receptor deficiencyPCSK1 deficiency (PCSK1D)
Beyond the preview
Go deeper on NCT04348175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348175.